Anticancer drug discovery in the future: an evolutionary perspective

Drug Discovery Today

Volumn 14, Issue 23-24, 2009, Pages 1136-1142

  Ma, Xianghui ^a   Wang, Zhiwen ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DOCETAXEL; EPOSIN; ETOPHOS; ETOPOSIDE; IRINOTECAN; NATURAL PRODUCT; PACLITAXEL; PODOPHYLLOTOXIN; TOPOTECAN; TRABECTEDIN; UNCLASSIFIED DRUG; VINBLASTINE; VINCA ALKALOID; VINCRISTINE;

BREAST CANCER; CANCER RESEARCH; CATHARANTHUS ROSEUS; DNA DAMAGE; DRUG APPROVAL; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG SCREENING; EWING SARCOMA; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC VARIABILITY; GLIOBLASTOMA; HUMAN; LUNG CANCER; LYMPHOMA; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; NATURAL SELECTION; NONHUMAN; NONLYMPHATIC LEUKEMIA; OVARY CANCER; PHYTOCHEMISTRY; PODOPHYLLUM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TAXUS BREVIFOLIA; TESTIS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; DRUG DESIGN; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; FORECASTING; HUMANS; NEOPLASMS;

EID: 71749104056     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.09.006     Document Type: Review

References (61)

1. Chabner B.A., and Roberts T.G. Timeline-chemotherapy and the war on cancer. Nat. Rev. Cancer 5 (2005) 65-72
2. Sawyers C. Targeted cancer therapy. Nature 432 (2004) 294-297
3. Zimmermann G.R., et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12 (2007) 34-42
4. Tabrizi M.A., and Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 12 (2007) 540-547
5. Fernandez A., et al. Is there a case for selectively promiscuous anticancer drugs?. Drug Discov. Today 14 (2009) 1-5
6. Yamanaka T., et al. Methodological aspects of current problems in target-based anticancer drug development. Int. J. Clin. Oncol. 11 (2006) 167-175
7. Haefner B. Drugs from the deep: marine natural products as drug candidates. Drug Discov. Today 8 (2003) 536-544
8. Molinski T.F., et al. Drug development from marine natural products. Nat. Rev. Drug Discov. 8 (2009) 69-85
9. Lee S.Y., et al. Metabolic engineering of microorganisms: general strategies and drug production. Drug Discov. Today 14 (2009) 78-88
10. Mann J. Natural products in cancer chemotherapy: past, present and future. Nat. Rev. Cancer 2 (2002) 143-148
11. Wani M.C., et al. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus breoifolia. J. Am. Chem. Soc. 93 (1971) 2325-2327
12. Schiff P.B., et al. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
13. Altmann K.H., and Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat. Prod. Rep. 24 (2007) 327-357
14. Miller C.N. Mesozoic conifers. Bot. Rev. 43 (1977) 217-280
15. Cheng Y.C., et al. Phylogeny of taxaceae and cephalotaxaceae tenera inferred from chloroplast matK gene and nuclear rDNA ITS region. Mol. Phylogenet. Evol. 14 (2000) 353-365
16. Wall M.E., et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88 (1966) 3888-3890
17. Lorence A., and Nessler C.L. Molecules of interest-camptothecin, over four decades of surprising findings. Phytochemistry 65 (2004) 2735-2749
18. Hsiang Y.H., et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260 (1985) 14873-14878
19. Eyde R.H. Fossil record and ecology of nyssa (cornaceae). Bot. Rev. 63 (1997) 97-123
20. Chen G.L., et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259 (1984) 13560-13565
21. Burden D.A., et al. Topoisomerase II etoposide interactions direct the formation of drug-induced enzyme-DNA cleavage complexes. J. Biol. Chem. 271 (1996) 29238-29244
22. Gordaliza M., et al. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon 44 (2004) 441-459
23. Xiang Q.Y., et al. Timing the eastern Asian-Eastern North American floristic disjunction: molecular clock corroborates paleontological estimates. Mol. Phylogenet. Evol. 15 (2000) 462-472
24. Facchini P.J., and De Luca V. Opium poppy and Madagascar periwinkle: model non-model systems to investigate alkaloid biosynthesis in plants. Plant J. 54 (2008) 763-784
25. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
26. Rinerhart K.L., et al. Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent antitumor agents from the Caribbean tunicate Ecteinascidia turbinata. J. Org. Chem. 55 (1990) 4512-4515
27. Wright A.E., et al. Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinata. J. Org. Chem. 55 (1990) 4508-4512
28. Martin R.D. The evolution of human reproduction: a primatological perspective. Am. J. Phys. Anthropol. Suppl. 45 (2007) 59-84
29. Ingman M., et al. Mitochondrial genome variation and the origin of modern humans. Nature 408 (2000) 708-713
30. Nowell P.C. The clonal evolution of tumor cell populations. Science 194 (1976) 23-28
31. Crespi B., and Summers K. Evolutionary biology of cancer. Trends Ecol. Evol. 20 (2005) 545-552
32. Sieber O.M., et al. Genomic instability-the engine of tumorigenesis?. Nat Rev. Cancer 3 (2003) 701-708
33. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
34. Michor F., et al. Dynamics of cancer progression. Nat. Rev. Cancer 4 (2004) 197-205
35. Merlo L.M.F., et al. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 6 (2006) 924-935
36. Loeb L.A., et al. Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 68 (2008) 3551-3557
37. Hays L.E., et al. Cigarette smoke induces genetic instability in airway epithelial cells by suppressing FANCD2 expression. Br. J. Cancer 98 (2008) 1653-1661
38. Durante M., and Cucinotta F.A. Heavy ion carcinogenesis and human space exploration. Nat. Rev. Cancer 8 (2008) 465-472
39. Maley C.C., et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat. Genet. 38 (2006) 468-473
40. Stoler D.L., et al. The onset and extent of genomic instability in sporadic colorectal tumor progression. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 15121-15126
41. Wood L.D., et al. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
42. Greenman C., et al. Patterns of somatic mutation in human cancer genomes. Nature 446 (2007) 153-158
43. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 (2008) 1061-1068
44. Campbell P.J., et al. Identification of somatically acquired rearrangements in cancer using genome-wide massively parallel paired-end sequencing. Nat. Genet. 40 (2008) 722-729
45. Knudson A.G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1 (2001) 157-162
46. Friedberg E.C. DNA damage and repair. Nature 421 (2003) 436-440
47. McMurray H.R., et al. Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype. Nature 453 (2008) 1112-1116
48. Braig M., and Schmitt C.A. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res. 66 (2006) 2881-2884
49. Macleod K. Tumor suppressor genes. Curr. Opin. Genet. Dev. 10 (2000) 81-93
50. Bernardi G. The neoselectionist theory of genome evolution. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 8385-8390
51. Baer C.F., et al. Mutation rate variation in multicellular eukaryotes: causes and consequences. Nat. Rev. Genet. 8 (2007) 619-631
52. Nei M. The new mutation theory of phenotypic evolution. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12235-12242
53. Nei M. Selectionism and neutralism in molecular evolution. Mol. Biol. Evol. 22 (2005) 2318-2342
54. Kimura M. Evolution rate at the molecular level. Nature 217 (1968) 624-626
55. Ohta T. Slightly deleterious mutant substitutions in evolution. Nature 246 (1973) 96-98
56. Hakem R. DNA-damage repair; the good, the bad, and the ugly. EMBO J. 27 (2008) 589-605
57. Su T.T. Cellular responses to DNA damage: one signal, multiple choices. Annu. Rev. Genet. 40 (2006) 187-208
58. d'Adda F.F. Living on a break: cellular senescence as a DNA-damage response. Nat. Rev. Cancer 8 (2008) 512-522
59. Mayr E. The objects of selection. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 2091-2094
60. Strickberberger M.W. Evolution (1995), Jones and Bartlett Publishers
61. Schreiber S.L. Small molecules: the missing link in the central dogma. Nat. Chem. Biol. 1 (2005) 64-66